Evidence map›Paper›PMID 34405281›Full record

ArticleParasitology research2021

Antitumor effects of a Toxoplasma mutant lacking lactate dehydrogenases.

Yaqiong Li, Yue Zhang, Ningbo Xia, Taifang Zhou, Bang Shen

Abstract read
PubMed Publisher
In one paragraph

Article in Parasitology research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pathogens (Basel, Switzerland) · 2026
    Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Parasites revive hope for cancer therapy.European journal of medical research · 2024
    Review
  10. Article
  11. Review
  12. Review
  13. A novel enemy of cancer: recent investigations into protozoan anti-tumor properties.Frontiers in cellular and infection microbiology · 2023
    Review
  14. Anti-Tumor Effect of Parasitic Protozoans.Bioengineering (Basel, Switzerland) · 2022
    Review
  15. Frontiers in cellular and infection microbiology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yaqiong Li *State Key Laboratory of Agricultural Microbiology, Huazhong Agricultural University, Wuhan, China.
Yue Zhang *State Key Laboratory of Agricultural Microbiology, Huazhong Agricultural University, Wuhan, China.
Ningbo XiaState Key Laboratory of Agricultural Microbiology, Huazhong Agricultural University, Wuhan, China.
Taifang ZhouState Key Laboratory of Agricultural Microbiology, Huazhong Agricultural University, Wuhan, China.
Bang ShenState Key Laboratory of Agricultural Microbiology, Huazhong Agricultural University, Wuhan, China. shenbang@mail.hzau.edu.cn.ORCID http://orcid.org/0000-0003-0103-271X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

"Bug as drug" is a concept recognized over a century ago and has gained significant research attention recently for fighting diseases such as immune disorders and others. Bacteria and viruses are constantly studied for this purpose, but the use of parasitic organisms is still rare. Recently, we found that Toxoplasma gondii mutants lacking two lactate dehydrogenases (ME49 Δldh1-Δldh2) were avirulent in mice but able to stimulate high levels of Th1 immunity. This outcome prompted us to determine whether Δldh mutants also displayed antitumor activities. Using a mouse melanoma model, we showed that intratumoral administration of Δldh1-Δldh2 repressed the growth of established tumors and helped to inhibit lethal tumor development in the mice. The sera of parasite-treated mice had high levels of TNF-α and INF-γ, which likely contributed to the tumor-repressing activity. We also found that chronic Toxoplasma infection, which is common in animals and humans, also led to antitumor activity. In addition, pre-existing chronic infections did not affect the antitumor efficiency of the Δldh1-Δldh2 mutant. Together, these results suggest that the attenuated T. gondii mutant Δldh1-Δldh2 has the potential to be a good antitumor therapy and provide new insights into the development of novel tumor therapeutics.

Indexed as

ToxoplasmaAnimalsL-Lactate DehydrogenaseMelanomaMiceMice, Inbred C57BLNeoplasms, ExperimentalL-Lactate DehydrogenaseAttenuated parasiteLactate dehydrogenaseToxoplasmaTumor therapy

Identifiers

PMID34405281

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.